Last reviewed 2026-05-23 · How we verify

T-allo10 cells addback

Porteus, Matthew, MD · Phase 1 active Small molecule ✓ Verified May 2026

T-allo10 cells addback is a Small molecule drug developed by Porteus, Matthew, MD. It is currently in Phase 1 development.

T-allo10 cells addback is a treatment intervention used in conjunction with allogeneic stem cell transplant and the CliniMACS Prodigy System, specifically studied in the context of hematologic diseases. The mechanism of T-allo10 cells addback is classified as somatic cell supplemental therapy, according to ChEMBL.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	T-allo10 cells addback
Sponsor	Porteus, Matthew, MD
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

T-allo10 cells addback CI brief — competitive landscape report
T-allo10 cells addback updates RSS · CI watch RSS
Porteus, Matthew, MD portfolio CI

Frequently asked questions about T-allo10 cells addback

What is T-allo10 cells addback?

T-allo10 cells addback is a Small molecule drug developed by Porteus, Matthew, MD.

Who makes T-allo10 cells addback?

T-allo10 cells addback is developed by Porteus, Matthew, MD (see full Porteus, Matthew, MD pipeline at /company/porteus-matthew-md).

What development phase is T-allo10 cells addback in?

T-allo10 cells addback is in Phase 1.

Manufacturer: Porteus, Matthew, MD — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing